Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors

Area of Science:

• Cardiovascular Science
• Renal Physiology
• Endocrinology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially for type 2 diabetes, now treat heart failure and kidney disease.
• Cardiovascular remodelling involves molecular and cellular changes due to injury or stress.
• Stem and progenitor cells, particularly endothelial progenitor cells (EPCs), play a role in pathological remodelling.

Purpose of the Study:

• To review the cardioprotective effects of SGLT2 inhibitors in the context of cardiac remodelling.
• To critically discuss recent evidence on SGLT2 inhibitors and their impact on cardiovascular disease.
• To explore the potential role of SGLT2 inhibitors in modulating stem and progenitor cells.

Main Methods:

• Narrative review of existing scientific literature.
• Analysis of studies investigating SGLT2 inhibitors' effects on cardiac remodelling.
• Examination of research on SGLT2 inhibitors' impact on stem and progenitor cells, including EPCs.

Main Results:

• SGLT2 inhibitors demonstrate positive effects on molecular and cellular changes in cardiac remodelling.
• Evidence suggests SGLT2 inhibitors can modulate the morphology and function of endothelial progenitor cells (EPCs).
• Observed effects on EPCs may contribute to the beneficial cardiovascular outcomes associated with SGLT2 inhibitors.

Conclusions:

• SGLT2 inhibitors offer significant cardioprotective benefits beyond glucose control.
• Modulation of stem and progenitor cells, especially EPCs, is a potential mechanism for SGLT2 inhibitor efficacy.
• Further research is warranted to fully elucidate the role of SGLT2 inhibitors in cardiovascular disease prevention and treatment.